April 22 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES TOPLINE RESULTS FROM PHASE 3 ARISE TRIAL EVALUATING COBENFY (XANOMELINE AND TROSPIUM CHLORIDE) AS AN ADJUNCTIVE TREATMENT TO ATYPICAL ANTIPSYCHOTICS IN ADULTS WITH SCHIZOPHRENIA
BRISTOL-MYERS SQUIBB CO - COBENFY DID NOT REACH STATISTICAL SIGNIFICANCE IN PHASE 3 TRIAL
BRISTOL-MYERS SQUIBB CO - COBENFY SAFETY AND TOLERABILITY CONSISTENT WITH PREVIOUS TRIALS
Source text: ID:nBw8K3lGVa
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。